Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04433858
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-12-20
First Post:
2020-06-13
Brief Title:
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression P-TRD
Sponsor:
Sheppard Pratt Health System
Organization:
Sheppard Pratt Health System
Study Overview
Official Title:
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression P-TRD
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the efficacy of psilocybin 25 mg administered under supportive conditions to adult participants with severe TRD in improving depressive symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None